Climb Retained Earnings from 2010 to 2024

CLYM Stock   2.10  0.17  7.49%   
Climb Bio Retained Earnings yearly trend continues to be very stable with very little volatility. Retained Earnings are likely to grow to about -148.2 M this year. Retained Earnings is the cumulative amount of net income that Climb Bio retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals
 
Retained Earnings  
First Reported
2010-12-31
Previous Quarter
-156 M
Current Value
-148.2 M
Quarterly Volatility
47.5 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Climb Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Climb Bio's main balance sheet or income statement drivers, such as Selling General Administrative of 16.1 M, Total Revenue of 0.0 or Research Development of 20.4 M, as well as many indicators such as . Climb financial statements analysis is a perfect complement when working with Climb Bio Valuation or Volatility modules.
  
Check out the analysis of Climb Bio Correlation against competitors.
To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.

Latest Climb Bio's Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Climb Bio over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Climb Bio's Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Climb Bio's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (155.98 M)10 Years Trend
Slightly volatile
   Retained Earnings   
       Timeline  

Climb Retained Earnings Regression Statistics

Arithmetic Mean(54,008,737)
Coefficient Of Variation(87.92)
Mean Deviation37,946,680
Median(28,136,000)
Standard Deviation47,483,471
Sample Variance2254.7T
Range127.8M
R-Value(0.76)
Mean Square Error1023.8T
R-Squared0.58
Significance0.001
Slope(8,074,666)
Total Sum of Squares31565.5T

Climb Retained Earnings History

2024-148.2 M
2023-156 M
2022-120.9 M
2021-75.6 M

About Climb Bio Financial Statements

Climb Bio investors utilize fundamental indicators, such as Retained Earnings, to predict how Climb Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Retained Earnings-156 M-148.2 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Climb Bio is a strong investment it is important to analyze Climb Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Climb Bio's future performance. For an informed investment choice regarding Climb Stock, refer to the following important reports:
Check out the analysis of Climb Bio Correlation against competitors.
To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.
You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Climb Bio. If investors know Climb will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Climb Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Climb Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Climb Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Climb Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.